Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6

     Arena Pharmaceuticals to Host Corporate Update and Financial Results
              Conference Call and Webcast on Tuesday, November 6

PR Newswire

SAN DIEGO, Oct. 31, 2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ --Arena Pharmaceuticals, Inc. (NASDAQ:
ARNA) today announced  that it will provide a corporate update and report
third quarter 2012 financial results after the NASDAQ Global Select Market
closes on Tuesday, November 6, 2012. The company will host a conference call
and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that day to
discuss the corporate update and financial results.

The conference call may be accessed by dialing 877.643.7155 for domestic
callers and 914.495.8552 for international callers. Please specify to the
operator that you would like to join the "Arena Pharmaceuticals' Third Quarter
2012 Financial Results Call." The conference call will be webcast live under
the investor relations section of Arena's website at www.arenapharm.com, and
will be archived there for 30 days following the call. Please connect to
Arena's website several minutes prior to the start of the broadcast to ensure
adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing and commercializing novel drugs for weight management,
cardiovascular disease, inflammation and other disorders. BELVIQ^® (lorcaserin
HCl), Arena's internally discovered drug, was approved by the US Food and Drug
Administration in June 2012, and is under review for regulatory approval in
additional jurisdictions. Arena's US operations are located in San Diego,
California, and its operations outside of the United States, including its
commercial manufacturing facility, are located in Zofingen, Switzerland. For
more information about Arena, please visit www.arenapharm.com.

Arena Pharmaceuticals^® and Arena^® are registered service marks of Arena
Pharmaceuticals, Inc., and BELVIQ^® is a registered trademark of Arena
Pharmaceuticals GmbH.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that
involve a number of risks and uncertainties. Such forward-looking statements
include statements about the regulatory review and approval of BELVIQ; and
Arena's efforts, focus, goals, strategy, research and development programs,
and ability to discover and develop compounds and commercialize drugs. For
such statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, the following: risks related to commercializing drugs, including
regulatory, manufacturing and supply issues and the pace of market acceptance;
cash and revenues generated from lorcaserin, including the impact of
competition; the timing and outcome of regulatory review is uncertain;
government and commercial reimbursement and pricing decisions; risks related
to relying on collaborative agreements; the timing and receipt of payments and
fees, if any, from collaborators; the entry into or modification or
termination of collaborative arrangements; unexpected or unfavorable new data;
nonclinical and clinical data is voluminous and detailed, and regulatory
agencies may interpret or weigh the importance of data differently and reach
different conclusions than Arena, request additional information, have
additional recommendations or change their guidance or requirements before or
after approval; data and other information related to any of Arena's research
and development may not meet safety, efficacy or other regulatory requirements
or otherwise be sufficient for further development, regulatory review or
approval or continued marketing; Arena's ability to obtain and defend patents;
the timing, success and cost of Arena's research and development programs;
results of clinical trials and other studies are subject to different
interpretations and may not be predictive of future results; clinical trials
and other studies may not proceed at the time or in the manner expected or at
all; having adequate funds; and satisfactory resolution of litigation or other
disagreements with others. Additional factors that could cause actual results
to differ materially from those stated or implied by Arena's forward-looking
statements are disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's judgment as of
the time of this release. Arena disclaims any intent or obligation to update
these forward-looking statements, other than as may be required under
applicable law.

Contact: Arena Pharmaceuticals, Inc.   Media Contact: Russo Partners
Cindy McGee, Vice President        David Schull, President
Investor Relations & Alliance             david.schull@russopartnersllc.com
Management
cmcgee@arenapharm.com               858.717.2310
858.453.7200, ext. 1479



SOURCE Arena Pharmaceuticals, Inc.

Website: http://www.arenapharm.com
 
Press spacebar to pause and continue. Press esc to stop.